The medical device maker's adjusted earnings per share and revenue were more than expected, as sales of its cardiovascular products surged. Boston Scientific gave a mixed updated full-year forecast.
The company should continue to benefit from market share gains for some of its products, including Watchman. Our interactive dashboard analysis of the Boston Scientific’s FY 2024Q3 Earnings ...
SinglePoint Inc. (OTC Pink: SING) ("SinglePoint" or "the Company") subsidiary Boston Solar, a proud partner of the Boston Red Sox and a leading provider of solar energy solutions, is proud to announce ...
Vijay Kumar, an analyst at Evercore, said in an interview that Farapulse is likely Boston Scientific’s most important product from Wall Street’s perspective. The pulsed field ablation system ...
but investors pulled back due to a "pause" in a trial of key product in development. Boston Scientific's (NYSE: BSX) stock was down just over 1% as of 3:30, after it fell as far as 4% earlier in ...
Medical-products company Boston Scientific reported third-quarter results before market open Shares of Boston Scientific Corp. rose 1.1% in premarket trades Wednesday after the medical products ...